Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Cleared to Begin Phase IIa Trial of HBV Drug


Arrowhead Research this week announced that it has received clearance from regulators in Hong Kong to begin a phase IIa trial of its siRNA-based hepatitis B treatment ARC-520.

The single-dose, dose-escalation trial is designed to determine the drug's ability to suppress hepatitis B surface antigen in combination with the oral antiviral agent entecavir in chronic HBV patients.

Single doses of ARC-520 will be evaluated at up to two ascending doses of 1.0 mg/kg and 2.0 mg/kg, Arrowhead said. At each of the two dose levels to be evaluated, a cohort of 8 patients will be enrolled with 6 being dosed with ARC-520 and 2 being dosed with placebo.

With the regulatory approval in hand, Arrowhead said it expects to begin dosing patients "shortly," and that top-line results from the study will be available in the third quarter of the year.